Camber Pharmaceuticals, Inc.
800 Centennial Avenue, Suite 1
Piscataway, NJ 08854
Tel: 732-529-0430

Office of the Attorney General
State of Vermont

To Whom It May Concern,

Pursuant to 18 V.S.A. §4637 (b) and (c), Camber Pharmaceuticals, Inc. is hereby providing notification and subsequent supplemental information regarding the introduction of a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

These products were launched in 2022 but were not reported. As we become aware of the laws and regulations surrounding drug price transparency, it is our intention to be in compliance with all state agencies.

NDC	Description	Market Launch Date	Wholesale Acquisition Cost
31722088930	Fingolimod 0.5 mg, 30 count	10/17/2022	$3681.73
31722087227	Pirfenidone 267 mg, 270 count	10/1/2022	$1800.00
31722087390	Pirfenidone 801 mg, 90 count	10/1/2022	$1800.00
31722057960	Maraviroc 150 mg, 60 count	2/7/2022	$1410.82
31722058060	Maraviroc 300 mg, 60 count	2/7/2022	$1410.82

Additional Information Required	Camber's Submission
A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	At market launch, Camber communicates with customers through press releases, internet marketing via our website, and through private conversations with corporate buyers. These products are sold in the United States only. Camber Pharmaceuticals, Inc. considers various factors in deciding the price at which to set its prescription drugs, including, but not limited to: the current competitive landscape and pricing environment; manufacturing considerations; supply considerations; profitability; costs, including research and development costs; contracts and relationships with customers; public policy considerations; and legal considerations.
The estimated volume of patients who may be prescribed the drug	Fingolimod: 1,000,000 patients Pirfenidone: 100,000 patients Maraviroc: 1,200,000 patients Camber Pharmaceuticals, Inc. does not evaluate the number of patients that may be prescribed these products. The estimation is based on the therapeutic category and the number of cases in the United States of the disease state that the medication is indicated for.

Camber Pharmaceuticals, Inc.
800 Centennial Avenue, Suite 1
Piscataway, NJ 08854
Tel: 732-529-0430

Additional Information Required	Camber's Submission
Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	None of these products were granted breakthrough therapy designation nor priority review.
The date and price of acquisition if the drug was not developed by the manufacturer	N/A. This product was not acquired.

If any additional information is needed, please let me know.

Christopher Bormida
Commercial Strategy and Operations Analyst
cbormida@camberpharma.com